European collaborations on medicine and vaccine procurement.
| Autor: | Vogler S; WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Gesundheit Österreich GmbH, Stubenring 6, 1010 Vienna, Austria., Haasis MA; WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Gesundheit Österreich GmbH, Stubenring 6, 1010 Vienna, Austria., van den Ham R; WHO Collaborating Centre for Pharmaceutical Policy and Regulation, Utrecht University, Utrecht, Netherlands., Humbert T; World Health Organization Regional Office for Europe, Copenhagen, Denmark., Garner S; World Health Organization Regional Office for Europe, Copenhagen, Denmark., Suleman F; WHO Collaborating Centre for Pharmaceutical Policy and Evidence Based Practice, University of KwaZulu-Natal, Durban, South Africa. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Bulletin of the World Health Organization [Bull World Health Organ] 2021 Oct 01; Vol. 99 (10), pp. 715-721. Date of Electronic Publication: 2021 Aug 20. |
| DOI: | 10.2471/BLT.21.285761 |
| Abstrakt: | To ensure equitable access to medicines and vaccines, organizational efforts and purchase volumes have been pooled in joint procurements and negotiations for decades in some regions of the world, as well as globally through supranational procurement mechanisms. In Europe, countries started to collaborate on procurement and negotiations recently when it became increasingly difficult to ensure access to high-priced medicines, even in high-income countries. Two European country collaborations (the Nordic Pharmaceutical Forum and the Baltic Procurement Initiative) have successfully concluded at least one joint tender process for medicines and vaccines and the Beneluxa Initiative has concluded its first successful joint price negotiation. This article describes the experiences of these country collaborations. Challenges observed included: legal barriers; institutional and organizational differences between health-care systems in member countries; and the risk that suppliers will be reluctant to cooperate with country collaborations. Although these collaborations helped improve access to medicines and vaccines for the countries involved, in situations such as a global health crisis, larger-scale, more-inclusive initiatives are needed. In the current coronavirus disease 2019 (COVID-19) pandemic, COVID-19 Vaccines Global Access (COVAX) initiative established a global procurement mechanism to ensure the equitable distribution of COVID-19 vaccines globally. Despite differences in organization and scale, the European country collaborations and COVAX have some similarities: (i) their success depends on the increased purchasing power associated with pooled order volumes; (ii) expert knowledge and previous procurement experience is pooled; (iii) they perform other collaborative activities that go beyond procurement alone; and (iv) they actively involve external partners and stakeholders. ((c) 2021 The authors; licensee World Health Organization.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|